Kyongbo Pharmaceutical Co., Ltd (KRX:214390)
South Korea flag South Korea · Delayed Price · Currency is KRW
5,070.00
-90.00 (-1.74%)
Last updated: Aug 21, 2026, 3:00 PM KST

Kyongbo Pharmaceutical Balance Sheet

Millions KRW. Fiscal year is Jan - Dec.

Assets

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Equivalents
6,9227,2284,1284,4776,3484,290
Short-Term Investments
5208202,000870870-
Cash & Short-Term Investments
13,8288,0486,1285,3477,2184,290
Cash Growth
214.21%31.34%14.60%-25.92%68.25%-79.55%
Accounts Receivable
70,75563,26851,62456,16050,20246,906
Other Receivables
507.621,392686.7697.94597.63988.69
Receivables
71,26364,66052,31156,85850,79947,895
Inventory
76,56080,97790,58570,66457,44357,670
Prepaid Expenses
1,265694.321,3111,610115.43913.7
Other Current Assets
6,9844,7581,6061,423749.74397.53
Total Current Assets
169,900159,138151,941135,902116,326111,166
Property, Plant & Equipment
164,648128,02399,85296,07393,91995,677
Long-Term Investments
9,53810,20211,12113,67611,93514,384
Other Intangible Assets
4,9843,8804,0083,6413,2213,355
Long-Term Deferred Tax Assets
12,68213,58713,56513,20311,95110,179
Other Long-Term Assets
5,8154,7083,3993,8103,1942,218
Total Assets
367,568319,538283,887266,305240,545236,979

Liabilities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Accounts Payable
18,76814,77114,95122,77514,74216,404
Accrued Expenses
3,3984,1023,5373,3982,7932,553
Short-Term Debt
131,436101,32189,27173,09563,90055,234
Current Portion of Long-Term Debt
--45909090
Current Portion of Leases
929.61,0101,0741,078280.59787.02
Current Income Taxes Payable
173.89-86.85118.34166.28-
Other Current Liabilities
38,84026,04523,69517,70713,59613,746
Total Current Liabilities
193,546147,249132,660118,26195,56988,814
Long-Term Debt
24,00024,000-45135225
Long-Term Leases
1,635340.271,0431,629106.58250.75
Pension & Post-Retirement Benefits
-114.831,482--927.43
Other Long-Term Liabilities
1,3962,0962,5481,9881,0301,061
Total Liabilities
220,577173,800137,733121,92496,84191,278

Shareholders' Equity

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Common Stock
11,95311,95311,95311,95311,95311,953
Additional Paid-In Capital
40,06740,06740,06740,06740,06740,067
Retained Earnings
100,01698,12598,33396,03394,69594,587
Comprehensive Income & Other
-5,046-4,408-4,199-3,672-3,012-907.41
Shareholders' Equity
146,991145,738146,154144,381143,704145,701
Total Liabilities & Equity
367,568319,538283,887266,305240,545236,979

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Total Debt
158,001126,67191,43375,93664,51256,587
Net Cash (Debt)
-144,173-118,623-85,305-70,589-57,294-52,296
Net Cash Growth
------
Net Cash Per Share
-6028.88-4961.88-3567.15-2952.68-2439.66-2190.88
Filing Date Shares Outstanding
23.9823.9123.9123.9123.9123.91
Total Common Shares Outstanding
23.9823.9123.9123.9123.9123.91
Working Capital
-23,64611,88919,28117,64120,75722,352
Book Value Per Share
6129.286096.066113.486039.336011.006094.52
Tangible Book Value
142,006141,858142,146140,741140,483142,346
Tangible Book Value Per Share
5921.445933.765945.845887.055876.265954.19
Land
35,05130,14630,14628,63327,56923,874
Buildings
102,33192,72582,77981,33679,34176,851
Machinery
141,623136,978125,238119,358113,325111,022
Construction In Progress
46,87024,8507,9591,8561,4441,729